🇺🇸 Interferon Beta 1 in United States
13 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 13
Most-reported reactions
- Blood Pressure Increased — 2 reports (15.38%)
- Injection Site Erythema — 2 reports (15.38%)
- Myocardial Infarction — 2 reports (15.38%)
- Body Temperature Increased — 1 report (7.69%)
- Cardiac Procedure Complication — 1 report (7.69%)
- Condition Aggravated — 1 report (7.69%)
- Coronary Artery Thrombosis — 1 report (7.69%)
- Covid-19 — 1 report (7.69%)
- Death — 1 report (7.69%)
- Depressed Level Of Consciousness — 1 report (7.69%)
Other Immunology approved in United States
Frequently asked questions
Is Interferon Beta 1 approved in United States?
Interferon Beta 1 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Interferon Beta 1 in United States?
University of Turin, Italy is the originator. The local marketing authorisation holder may differ — check the official source linked above.